← Eichor
Study identifier: NCT06607731 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy

Condition: Bone Angioma  ·  Sponsor: Centre Hospitalier Universitaire de Saint Etienne

PhaseN/A
Planned participants11
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The investigators aimed to evaluate efficacy and safety of a non-surgical protocol treatment combining transarterial embolization and percutaneous radiopaque gelled ethanol (RGE) sclerotherapy in a first procedure, then followed by vertebroplasty in a second procedure, to treat aggressive vertebral hemangioma patients in tertiary hospital. Exclusion criteria were age \<18-years old and any association with neurological deficit.

This description comes directly from the study's public registry record.

Talk to the study team

Sylvain GRANGE, MD  ·  (0)477829066  ·  sylvain.grange@chu-st-étienne.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHU de Saint-EtienneSaint-Priest-en-Jarez, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06607731